严俊，博士

课题组长

地址：上海东安路130号（200032）

电话：021-54237454

邮箱：yan_jun@fudan.edu.cn

教育经历

• 2002年：中国科学院生物化学与细胞生物学研究所，细胞学专业，博士学位

• 1997年：复旦大学遗传学系，遗传学专业，学士学位

工作经历

• 2019-至今：青年研究员，复旦大学，实验动物科学部

• 2009-2019：副教授，南京大学，模式动物研究所

• 2008-2009：Associate Research Scientist, 美国哥伦比亚大学医学院

• 2003-2008：Research Associate, 美国德州医学中心贝勒医学院

学术团体任职

• 2018-现在，中国抗癌协会第一届和第二届肿瘤代谢专业委员会委员

• 2015-现在，Frontiers in Oncology, Reviewer Editor

科研项目

      主持了5项国家自然科学基金面上项目，此外主持了教育部博士点基金项目、上海市科委动物专项、上海市科委生物医药专项和江苏省自然科学基金各1项，并参与了973计划、国家重点研发计划、教育部、吴阶平医学基金会和省卫生厅等项目。

奖励和荣誉

• 2022年，全国妇幼健康科学技术奖自然科学奖二等奖第八完成人（获奖项目：PI3K/mTOR信号通路调控原始卵泡库动态平衡的分子机制及临床应用）

发表论文

代表性成果（*，通讯作者；#，第一作者）

1. Liu J^#, Li M^#, Wu J^#, Qi Q, Li Y, Wang S, Liang S, Zhang Y, Zhu Z, Huang R*, Yan J*, Zhu R*. Identification of ST3GAL5 as a prognostics biomarker correlating with CD8+ T cell exhaustion in clear cell renal cell carcinoma. Front. Immunol. 2022 (In Press) doi: 10.3389/fimmu.2022.979605.

2. Yang L^#, Sun J^#, Li M, Long Y, Zhang D, Guo H*, Huang R*, Yan J*. Oxidized low-density lipoprotein links hypercholesterolemia and bladder cancer aggressiveness by promoting cancer stemness. Cancer Res. 2021 Nov 15;81(22):5720-5732. doi: 10.1158/0008-5472.CAN-21-0646. link

3. Huang Z^#, Yan YL^#, Zhu Z^#, Liu J, He X, Dalangood S, Li M, Tan M, Cai J, Tang P, Huang R, Shen B, Huang R*, Shen B*, Yan J*. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling. Cell Death Dis. 2021 May 25;12(6):537. doi:10.1038/s41419-021-03819-0. link

4. Dalangood S^#, Zhu Z^#, Ma Z, Li J, Zeng Q, Yan Y, Shen B, Yan J*, Huang R*. Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer. Theranostics 2020 Aug 8;10(22):10078-10091. doi:10.7150/thno.48711. link

5. Huang X^#, Zhu H^#, Gao Z, Li J, Zhuang J, Dong Y, Shen B, Li M, Zhou H, Guo H*, Huang R*, Yan J*. Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p. J. Biol. Chem. 2018 May 4;293(18):6693. doi:10.1074/jbc.RA118.001689. link

6. Chang C^#, Liu J, He W, Qu M, Huang X, Deng Y, Shen L, Zhao X, Guo H, Jiang J, Fu XY, Huang R, Zhang D, Yan J*. A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression. Oncogene 2018 Jan 25;37(4):415-26. doi:10.1038/onc.2017.332. link

7. Zhuang J^#, Shen L^#, Yang L, Huang X, Lu Q, Cui Y, Zheng X, Zhao X, Zhang D, Huang R, Guo H*, Yan J*. TGFβ1 promotes gemcitabine resistance through regulating the lncRNA-LET/NF90/miR-145 signaling axis in bladder cancer. Theranostics 2017 Jul 22;7(12):3053-3067. doi:10.7150/thno.19542. link

8. Han Y^#, Huang W^#, Liu J, Liu D, Cui Y, Huang R, Yan J*, Lei M*. Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells. Theranostics 2017 Apr 20;7(7):1914-1927. doi:10.7150/thno.17852. link

9. Zhao W^#, Chang C, Cui Y, Zhao X, Yang J, Shen L, Zhou J, Hou Z, Zhang Z, Ye C, Hasenmayer D, Perkins R, Huang X, Yao X, Yu L, Huang R, Zhang D, Guo H*, Yan J*. Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α. J. Biol. Chem. 2014 Apr 18;289(16):11219-11229. doi: 10.1074/jbc.M113.535989. link

10. Yan J^#, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, Yu-Lee LY, Tsai SY, Tsai MJ*. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 2008 Jul 1;68(13):5460-8. doi: 10.1158/0008-5472.CAN-08-0955. link

11. Yan J^#, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ*. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res. 2006 Nov 15;66(22):11039-46. doi: 10.1158/0008-5472.CAN-06-2442. link

12. Yan J^#, Yu Y, Wang N, Chang Y, Ying H, Liu W, He J, Li S, Jiang W, Li Y, Liu H, Wang H, Xu Y*. LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma. Oncogene 2004 Mar 11;23(10):1939-49. doi: 10.1038/sj.onc.1207306. link

13. Yan J^#, Ying H, Gu F, He J, Li YL, Liu HM, Xu YH*. Cloning and characterization of a mouse liver-specific gene mfrep-1, up-regulated in liver regeneration. Cell Res. 2002 Dec;12(5-6):353-61. doi: 10.1038/sj.cr.7290137. link

综述与著作

1. Yan J^#, Tsai SY, and Tsai MJ*. A central role of SRC-3/AIB1 in tumorigenesis. In: Kumar R and O’Malley BW, eds. Nuclear receptor coregulators and human diseases. Singapore: World Scientific; 2008. p.219-241.

2. Yan J^#, Tsai SY, Tsai MJ*. SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharm. Sin. 2006 Apr;27(4):387-94. doi: 10.1111/j.1745-7254.2006.00315.x. (Invited Review)

参与成果（#，第一作者；*，通讯作者；Ɨ, Co-senior author）

1. Lu Y^#, Lin Y, Zhang X, Yan J, Kong Z, Zhang L, Wang C, Huang Y, Zhao S*, Li Y*. LncRNA-AP006284.1 promotes prostate cancer cell growth and motility by forming RNA-DNA triplexes and recruiting GNL3/SFPQ complex to facilitate RASSF7 transcription. Genes Dis. 2022 (In Press) doi.org/10.1016/j.gendis.2022.04.005 

2. Zhu H^#, Ren S^#, Bitler BG, Aird KM, Tu Z, Skordalakes E, Zhu Y, Yan J, Sun Y*, Zhang R*. SPOP E3 ubiquitin ligase adaptor promotes cellular senescence by degrading the SENP7 deSUMOylase. Cell Rep. 2015 Nov 10;13(6):1183-1193. doi: 10.1016/j.celrep.2015.09.083.

3. An J^#, Ren S^#, Murphy SJ^#, Dalangood S^#, Chang C, Pang X, Cui Y, Wang L, Pan Y, Zhang X, Zhu Y, Wang C, Halling GC, Cheng L, Sukov WR, Karnes RJ, Vasmatzis G, Zhang Q, Zhang J, Cheville JC, Yan J^Ɨ, Sun Y*^,Ɨ, Huang H*^,Ɨ. Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 2015 Sep 17;59(6):904-16. doi: 10.1016/j.molcel.2015.07.025. 

4. Kinkade CW^#, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C*. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 2008 Sep;118(9):3051-64. doi: 10.1172/JCI34764. 

5. Ayala G^#,*, Yan J, Li R, Ding Y, Thompson TC, Mims MP, Hayes TG, MacDonnell V, Lynch RG, Frolov A, Miles BJ, Wheeler TM, Harper JW, Tsai MJ, Ittmann MM, Kadmon D. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin. Cancer Res. 2008 Nov 15;14(22):7511-8. doi: 10.1158/1078-0432.CCR-08-0839.